123 related articles for article (PubMed ID: 14621855)
1. Prolongation of murine thyroid allografts by interleukin 2 (DAB486)-toxin and RS-61443.
Hullett DA; Landry AS; Eckoff DE; Nichols JC; Eugui EM; Allison AC; Sollinger HW
Transpl Int; 1992; 5 Suppl 1():S487-9. PubMed ID: 14621855
[TBL] [Abstract][Full Text] [Related]
2. DAB486-IL-2 (IL-2-toxin) in combination with low-dose RS-61443 (mycophenolate mofetil) prolongs murine thyroid allograft survival.
Hullett DA; Landry AS; Eckhoff DE; Nichols JC; Eugui EM; Allison AC; Sollinger HW
Transplant Proc; 1993 Feb; 25(1 Pt 1):756-7. PubMed ID: 8438470
[No Abstract] [Full Text] [Related]
3. Interleukin-2-diphtheria toxin fusion protein prolongs murine islet cell engraftment.
Pankewycz O; Mackie J; Hassarjian R; Murphy JR; Strom TB; Kelley VE
Transplantation; 1989 Feb; 47(2):318-22. PubMed ID: 2493178
[TBL] [Abstract][Full Text] [Related]
4. Treatment with a diphtheria toxin-related interleukin 2 fusion protein prolongs cardiac allograft survival in mice.
Barrett LV; Murphy JR; Strom TB; Kirkman RL
Transplant Proc; 1989 Feb; 21(1 Pt 1):1130-1. PubMed ID: 2650076
[No Abstract] [Full Text] [Related]
5. Reversal of acute allograft rejection using immunotoxin.
Knechtle SJ; Fechner JH; Stavrou S; Neville DM; Dong Y; Hong X; Tsuchida M; Hamawy MM
Transplant Proc; 1998 Aug; 30(5):2150-1. PubMed ID: 9723422
[No Abstract] [Full Text] [Related]
6. Initial clinical experiences with an interleukin-2 fusion toxin (DAB486-IL-2).
Meneghetti CM; LeMaistre CF
Targeted Diagn Ther; 1992; 7():395-401. PubMed ID: 1633301
[No Abstract] [Full Text] [Related]
7. Prolongation of cardiac allograft survival in murine recipients treated with a diphtheria toxin-related interleukin-2 fusion protein.
Kirkman RL; Bacha P; Barrett LV; Forte S; Murphy JR; Strom TB
Transplantation; 1989 Feb; 47(2):327-30. PubMed ID: 2645719
[TBL] [Abstract][Full Text] [Related]
8. In vivo studies with chimeric toxins. Interleukin-2 fusion toxins as immunosuppressive agents.
Shapiro ME; Kirkman RL; Kelley VR; Bacha P; Nichols JC; Strom TB
Targeted Diagn Ther; 1992; 7():383-93. PubMed ID: 1633300
[No Abstract] [Full Text] [Related]
9. Interleukin-2 receptor-specific fusion toxin inhibits barotrauma-induced arterial atherosclerosis.
Miller DD; Bach RG; Tio FO; Bailey SR; Waters CA; Woodworth TG; Nichols JC; Paige SB; Farrar M
Atherosclerosis; 1996 Sep; 126(1):1-14. PubMed ID: 8879429
[TBL] [Abstract][Full Text] [Related]
10. Interleukin 2 receptor targeted fusion toxin (DAB486-IL-2) treatment blocks diabetogenic autoimmunity in non-obese diabetic mice.
Pacheco-Silva A; Bastos MG; Muggia RA; Pankewycz O; Nichols J; Murphy JR; Strom TB; Rubin-Kelley VE
Eur J Immunol; 1992 Mar; 22(3):697-702. PubMed ID: 1547815
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides.
Saleh MN; LeMaistre CF; Kuzel TM; Foss F; Platanias LC; Schwartz G; Ratain M; Rook A; Freytes CO; Craig F; Reuben J; Sams MW; Nichols JC
J Am Acad Dermatol; 1998 Jul; 39(1):63-73. PubMed ID: 9674399
[TBL] [Abstract][Full Text] [Related]
12. DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma.
Foss FM
Clin Lymphoma; 2000 Sep; 1(2):110-6; discussion 117. PubMed ID: 11707818
[TBL] [Abstract][Full Text] [Related]
13. Immune status assay (ISA): a noninvasive procedure for studying allograft rejection.
Fernandez LA; Tsuchida M; Manthei E; Fechner JH; Oberley TD; Leverson GE; Knechtle SJ; Hamawy MM
Transpl Immunol; 2004; 13(2):147-54. PubMed ID: 15380545
[TBL] [Abstract][Full Text] [Related]
14. Two novel therapies for the treatment of cutaneous T-cell lymphoma.
LeMaistre CF
Clin Lymphoma; 2000 Nov; 1 Suppl 1():S7. PubMed ID: 11707856
[No Abstract] [Full Text] [Related]
15. Suppression of immunopathology in schistosomiasis by interleukin-2-targeted fusion toxin, DAB389IL-2. I. Studies of in vitro and in vivo efficacy.
Ramadan MA; Gabr NS; Bacha P; Günzler V; Phillips SM
Cell Immunol; 1995 Dec; 166(2):217-26. PubMed ID: 7497523
[TBL] [Abstract][Full Text] [Related]
16. Graft survival in a rhesus renal transplant model after immunotoxin-mediated T-cell depletion is enhanced by mycophenolate and steroids.
Fechner JH; Dong Y; Hong X; Brunner KG; Tsuchida M; Neville D; Scharff J; Lee F; Oberley TD; Peters D; Schultz JM; Manthei ER; Hamawy MM; Knechtle SJ
Transplantation; 2001 Aug; 72(4):581-7. PubMed ID: 11544415
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy using interleukin-2 diphtheria toxin chimer prolongs murine allografts.
Mackie JD; Pankewycz OG; Hassarjian R; Murphy JR; Kelley VE; Strom TB
Transplant Proc; 1989 Feb; 21(1 Pt 3):2718-9. PubMed ID: 2495680
[No Abstract] [Full Text] [Related]
18. Diphtheria toxin-interleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised mice.
Black JH; McCubrey JA; Willingham MC; Ramage J; Hogge DE; Frankel AE
Leukemia; 2003 Jan; 17(1):155-9. PubMed ID: 12529673
[TBL] [Abstract][Full Text] [Related]
19. Effect of DAB(389)IL-2 immunotoxin on the course of experimental autoimmune encephalomyelitis in Lewis rats.
Phillips SM; Bhopale MK; Constantinescu CS; Ciric B; Hilliard B; Ventura E; Lavi E; Rostami A
J Neurol Sci; 2007 Dec; 263(1-2):59-69. PubMed ID: 17603081
[TBL] [Abstract][Full Text] [Related]
20. RS-61443 allows islet allografting and specific tolerance induction in adult mice.
Hao L; Lafferty KJ; Allison AC; Eugui EM
Transplant Proc; 1990 Apr; 22(2):876-9. PubMed ID: 2109426
[No Abstract] [Full Text] [Related]
[Next] [New Search]
